BerGenBio ASA
7BG0
Company Profile
Business description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company’s clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Contact
Mollendalsbakken 9
Bergen5009
NORT: +47 55961159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,308.90 | 21.00 | 0.25% |
| CAC 40 | 7,555.87 | 17.89 | -0.24% |
| DAX 40 | 22,425.83 | 154.16 | 0.69% |
| Dow JONES (US) | 40,527.62 | 300.03 | 0.75% |
| FTSE 100 | 8,463.46 | 46.12 | 0.55% |
| HKSE | 22,035.35 | 27.24 | 0.12% |
| NASDAQ | 17,461.32 | 95.19 | 0.55% |
| Nikkei 225 | 35,954.54 | 114.55 | 0.32% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,560.83 | 32.08 | 0.58% |
| S&P/ASX 200 | 8,095.10 | 24.50 | 0.30% |
| SSE Composite Index | 3,282.47 | 4.18 | -0.13% |